Berchuck, A., van der Baan, F. H., Johnatty, S. E., Chenevix-Trench, G., Pharoah, P. D. P., Rookus, M. A., & Goode, E. (2015). KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA). In Gynecologic Oncology (Vol. 137, pp. 26–27). Elsevier BV. https://doi.org/10.1016/j.ygyno.2015.01.062

Berchuck, A., F. H. van der Baan, S. E. Johnatty, G. Chenevix-Trench, P. D. P. Pharoah, M. A. Rookus, and E. Goode. “KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA).” In Gynecologic Oncology, 137:26–27. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.062.

Berchuck A, van der Baan FH, Johnatty SE, Chenevix-Trench G, Pharoah PDP, Rookus MA, et al. KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA). In: Gynecologic Oncology. Elsevier BV; 2015. p. 26–7.

Berchuck, A., et al. “KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA).” Gynecologic Oncology, vol. 137, Elsevier BV, 2015, pp. 26–27. Crossref, doi:10.1016/j.ygyno.2015.01.062.

Berchuck A, van der Baan FH, Johnatty SE, Chenevix-Trench G, Pharoah PDP, Rookus MA, Goode E. KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA). Gynecologic Oncology. Elsevier BV; 2015. p. 26–27.